NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.57
-0.43 (-2.26%)
At close: Feb 21, 2025, 4:00 PM
18.55
-0.02 (-0.11%)
After-hours: Feb 21, 2025, 5:48 PM EST
NAMS Analyst Ratings
Total Analysts
7
Consensus Rating
Strong Buy
Price Target
$41.33
Upside
+122.56%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +115.40% | Jan 28, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $40 | Buy | Reiterates | $40 | +115.40% | Jan 24, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $48 | Strong Buy | Reiterates | $48 | +158.48% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $48 | Strong Buy | Initiates | $48 | +158.48% | Dec 30, 2024 |
| Scotiabank | Scotiabank | Buy Maintains $35 → $47 | Buy | Maintains | $35 → $47 | +153.10% | Dec 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +93.86% | Dec 5, 2024 |
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +93.86% | Nov 21, 2024 |
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +93.86% | Nov 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $36 | Strong Buy | Reiterates | $36 | +93.86% | Nov 7, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $37 | Buy | Reiterates | $37 | +99.25% | Sep 23, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +66.94% | Sep 5, 2024 |
| Needham | Needham | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +93.86% | Aug 28, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +66.94% | Jul 30, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $31 | Buy | Reiterates | $31 | +66.94% | Jun 7, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | May 15, 2024 |
| Scotiabank | Scotiabank | Buy Initiates $35 | Buy | Initiates | $35 | +88.48% | Mar 14, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.